Engineered immune cells take on tough gut cancers in new trial
NCT ID NCT06055439
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, rectal, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to see if this therapy is safe and can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can diet and vitamin c supercharge rectal cancer treatment?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk